Special Issue

Skin Cancers: Biomarkers and Potential Therapeutic Targets

Message from the Guest Editors

Skin malignancies such as highly lethal and aggressive melanoma and non-melanoma continue to represent a major health concern worldwide. So investigations related to disease risk factors, novel biomarkers for early detection or therapy efficacy monitoring present potential directions advancing both skin cancer diagnosis and treatment. Recent progresses in melanoma in terms of immunotherapies aimed at checkpoint inhibitors have opened new sophisticated avenues to be explored for skin cancer in general and melanoma management in particular. Refined technologies and clinical approaches for cancer detection and monitoring are useful tools in deciphering biomarkers and potential therapeutic biomolecules or cellular pathways.

Recently, the COVID-19 pandemic has impacted the dermato-oncology field by challenging diagnoses, therapeutic approaches, surveillance and the management of skin tumors. This pandemic has further led to the exploration of new research areas, resulting in novel biomarkers' disease panel at the border between cancer and infectious disease.

In this SI dedicated to skin cancers and hosted by the JPM, current findings in research and clinical approaches are welcome.

Guest Editors

Dr. Carolina Constantin

Prof. Dr. Sabina Zurac

Prof. Dr. Monica Neagu

Deadline for manuscript submissions

closed (10 April 2023)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/111835

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

MDPI